This company has been acquired
Stealth BioTherapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
14.36%
Earnings growth rate
61.96%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 19.71% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
Recent updates
Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company
Sep 30Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private
Aug 01Stealth BioTherapeutics: A Net-Net Biopharma Going Private
Jul 26Stealth BioTherapeutics receives Nasdaq non-compliance receipt
Jul 11Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year
Dec 31
Revenue & Expenses Breakdown
How Stealth BioTherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 0 | -53 | 20 | 27 |
| 30 Sep 21 | 0 | -51 | 20 | 25 |
| 30 Jun 21 | 0 | -56 | 20 | 24 |
| 31 Mar 21 | 0 | -50 | 19 | 26 |
| 31 Dec 20 | 0 | -57 | 19 | 29 |
| 30 Sep 20 | 21 | -35 | 20 | 35 |
| 30 Jun 20 | 21 | -41 | 22 | 38 |
| 31 Mar 20 | 21 | -44 | 23 | 40 |
| 31 Dec 19 | 21 | -72 | 22 | 45 |
| 30 Sep 19 | 0 | -102 | 26 | 45 |
| 30 Jun 19 | 0 | -108 | 25 | 51 |
| 31 Mar 19 | 0 | -120 | 23 | 54 |
| 31 Dec 18 | 0 | -97 | 22 | 53 |
| 30 Sep 18 | 0 | -92 | 16 | 59 |
| 31 Dec 17 | 0 | -83 | 17 | 63 |
Quality Earnings: MITO is currently unprofitable.
Growing Profit Margin: MITO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MITO is unprofitable, but has reduced losses over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare MITO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MITO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Return on Equity
High ROE: MITO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/16 15:33 |
| End of Day Share Price | 2022/11/15 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stealth BioTherapeutics Corp is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Joshua Schimmer | Evercore ISI |